BlossomHill Therapeutics (NASDAQ:BLSM) Stock Gets Downgrade from Wall Street Zen

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Several other analysts also recently commented on the stock. HC Wainwright restated a “buy” rating on shares of BlossomHill Therapeutics in a research report on Wednesday, September 30th. Guggenheim upped their target price on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. Weiss Ratings started coverage on BlossomHill Therapeutics in a research note on Tuesday, November 3rd. They issued a “sell (e-)” rating for the company. Finally, Lifesci Capital assumed coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price target for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Get Our Latest Stock Report on BLSM

BlossomHill Therapeutics Stock Performance

NASDAQ BLSM opened at $14.02 on Friday. BlossomHill Therapeutics has a 12 month low of $11.02 and a 12 month high of $27.99. The company has a market cap of $445.56 million and a PE ratio of -1.60. The business’s 50 day moving average price is $18.01.

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.36). Sell-side analysts predict that BlossomHill Therapeutics will post -5.54 earnings per share for the current fiscal year.

About BlossomHill Therapeutics

(Get Free Report)

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.

Further Reading

Analyst Recommendations for BlossomHill Therapeutics (NASDAQ:BLSM)

Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.